TABLE 4.
HI titers of preimmune and convalescent-phase sera from volunteers given NVa
| Volunteer | Challenge outcomeb | HI titer
|
Fold HI titer increase | |
|---|---|---|---|---|
| Prechallenge | Postchallenge | |||
| 1 | Infected | <10 | 160 | 32 |
| 2 | Infected | 40 | 10,240 | 256 |
| 3 | Infected | 160 | 10,240 | 128 |
| 4 | Infected | 40 | 2,560 | 64 |
| 5 | Infected | 40 | 2,560 | 64 |
| 6 | Noninfected | 40 | 40 | 0 |
| 7 | Noninfected | 10 | 10 | 0 |
a
Heat-inactivated and kaolin-treated sera (1:10) were tested for their ability to inhibit rNV VLP HA by HI assay. Pre- and postchallenge sera were collected from human volunteers before and 2 to 4 weeks after NV (8fIIa) challenge and stored at −70°C (24).
b
Infected, seroresponse and/or antigen shedding with or without symptoms; noninfected, no seroresponse or antigen shedding with low symptom score (24).